What changed
The Pharmacy Compounding Advisory Committee advises FDA on whether bulk substances may be used in compounding under section 503A. For each nominated peptide, BPC-157, KPV, TB-500, MOTS-c, DSIP/emideltide, Semax, and Epitalon, the practical question is whether the substance lands on the 503A bulks list. A positive recommendation keeps a legal compounding-pharmacy channel open; a negative one effectively closes it, pushing remaining supply toward the gray market without eliminating it. The committee has form here: ipamorelin failed its 503A vote in 2024. A PCAC recommendation is not an instant rule change, FDA rulemaking follows, but it is the clearest signal available on where compounding access for these substances is heading. Peptides Media will update the affected pages and the regulatory tracker when the committee's votes are posted.
Affected pages
Sources
- 1.
FDA. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee 2026.
Accessed 2026-07-24.
FDA meeting page for the July 23-24, 2026 PCAC review of BPC-157, KPV, TB-500, MOTs-C, emideltide/DSIP, Semax, and Epitalon bulk substances, including the uses evaluated for each, briefing documents, and docket FDA-2025-N-6895.
- 2.
FDA. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks 2026.
Accessed 2026-06-08.
FDA summarizes potential significant safety risks and missing safety information for several nominated peptide bulk substances.
- 3.
FDA. October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) Meeting 2024.
Accessed 2026-06-09.
FDA meeting summary reporting PCAC votes against placing ipamorelin free base or ipamorelin acetate on the 503A Bulks List because the available information did not support safety and efficacy in the reviewed contexts.